Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q3 2022 Blueprint Medicines Corp Earnings Call & Investor Day Transcript

Nov 01, 2022 / 12:30PM GMT
Release Date Price: $48.24 (-6.94%)
Operator

Please welcome to the stage Senior Vice President, Investor Relations, Jim Baker.

Unidentified Company Representative

Good morning, everyone. Thank you for joining us in the room and on the webcast. We know that your time is really important. And we're grateful that you're choosing to spend your morning with us today. We're also thankful to all the Blueprint employees, who contributed to the presentation you're about to see and are listening in from home.

This morning, we announced financial results for the third quarter. And during the presentation today, we're excited to share a number of updates and our vision for achieving precision at scale. Our presenters include Kate Haviland, our Chief Executive Officer; Dr. Philina Lee, our Chief Commercial Officer; Dr. Becker Hewes, our Chief Medical Officer; Dr. Fouad Namouni, our President of R&D; Dr. Percy Carter, our Chief Scientific Officer; and Christy Rossi, our Chief Operating Officer; Mike Landsittel, our Chief Financial Officer is also here and available during the Q&A.

I want to take a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot